PSIQUIATRÍA Y NEUROCIENCIAS
PSIQUIATRÍA Y NEUROCIENCIAS
![Foto de PSIQUIATRÍA Y NEUROCIENCIAS](/img/grupo.png)
![Foto de Eli Lilly and Company](/img/noimage_org.png)
Eli Lilly and Company
Indianapolis, EE. UU.Publicaciones en colaboración con investigadores/as de Eli Lilly and Company (3)
2007
-
Effect of olanzapine or risperidone treatment on some cognitive functions in a one-year follow-up of schizophrenia outpatients with prominent negative symptoms
European Neuropsychopharmacology, Vol. 17, Núm. 11, pp. 725-734
1998
-
Pharmacoeconomic assessment of olanzapine in the treatment of refractory schizophrenia based on a pilot clinical study
Clinical Drug Investigation, Vol. 15, Núm. 1, pp. 29-35
1997
-
Olanzapine in treatment-refractory schizophrenia: Results of an open- label study
Journal of Clinical Psychiatry, Vol. 58, Núm. 11, pp. 479-483